Preventive effect of cryotherapy on persistent chemotherapy-induced peripheral neuropathy after completion of weekly paclitaxel therapy for breast cancer

Abstract BackgroundChemotherapy-induced peripheral neuropathy (CIPN) is an important adverse event of taxane-based chemotherapy, which can persist in a substantial proportion of patients for years. Cryotherapy therapy is shown to be effective in prevention of CIPN during chemotherapy, but its protective effect on persistent CIPN has not been reported. MethodsThis observational study was performed as an ancillary analysis of a randomized trial investigating the preventive effect of cryotherapy on weekly paclitaxel-induced CIPN in breast cancer patients (UMIN000034966). Eligible cases were evaluated for Functional Assessment of Cancer Therapy-Neurotoxicity (FACT-NTX) score and Patient Neurotoxicity Questionnaire (PNQ) at more than one year after completion of weekly paclitaxel. ResultsThirty-eight cases were evaluated for persistent CIPN with a median 2.3 (1.3-3.1) years after completion of weekly paclitaxel. The incidence of a significant decrease in FACT-NTX scores was numerically lower in the cryotherapy group compared with the control group (15.8% vs. 36.8%, p = 0.13). There was also a lower grade of PNQ sensory (p = 0.02) and motor (p = 0.17) in the cryotherapy group compared with the control group. ConclusionIn breast cancer patients treated with weekly paclitaxel, cryotherapy resulted in a numerical decrease in the incidence of persistent CIPN after completion of weekly paclitaxel therapy.

Download Full-text

Preventive Effect of Cryotherapy on Persistent Chemotherapy-induced Peripheral Neuropathy After Completion of Weekly Paclitaxel Therapy for Breast Cancer

10.21203/rs.3.rs-417227/v1 ◽

2021 ◽

Author(s):

Hideo Shigematsu ◽

Yuri Kimura ◽

Tomoko Itagaki ◽

Daisuke Yasui

Keyword(s):

Breast Cancer ◽

Peripheral Neuropathy ◽

Cancer Patients ◽

Weekly Paclitaxel ◽

Control Group ◽

Lower Grade ◽

Breast Cancer Patients ◽

Preventive Effect ◽

One Year ◽

Paclitaxel Treatment

Abstract BackgroundChemotherapy-induced peripheral neuropathy (CIPN) is an important adverse event of taxane-based chemotherapy, which can persist in a substantial proportion of patients for years. Cryotherapy therapy is shown to be effective in prevention of CIPN during chemotherapy, but its protective effect on persistent CIPN has not been reported. MethodsCases enrolled in a randomized trial investigating the preventive effect of cryotherapy on weekly paclitaxel-induced CIPN in breast cancer patients (UMIN000034966) were evaluated for Functional Assessment of Cancer Therapy-Neurotoxicity (FACT-NTX) score and Patient Neurotoxicity Questionnaire (PNQ) at more than one year after completion of weekly paclitaxel. ResultsThirty-eight cases were evaluated for persistent CIPN with a median 2.3 (1.3-3.1) years after completion of weekly paclitaxel. The incidence of a significant decrease in FACT-NTX scores was numerically lower in the cryotherapy group compared with the control group (15.8% vs. 36.8%, p = 0.13). There was also a lower grade of PNQ sensory (p = 0.02) and motor (p = 0.17) in the cryotherapy group compared with the control group. ConclusionIn breast cancer patients treated with weekly paclitaxel, cryotherapy resulted in a numerical decrease in the incidence of persistent CIPN at more than one year after completion of weekly paclitaxel treatment.

Download Full-text

Acupuncture and Reflexology for Chemotherapy-Induced Peripheral Neuropathy in Breast Cancer

Integrative Cancer Therapies ◽

10.1177/1534735417690254 ◽

2017 ◽

Vol 16 (3) ◽

pp. 258-262 ◽

Cited By ~ 16

Author(s):

Idan Ben-Horin ◽

Peretz Kahan ◽

Larisa Ryvo ◽

Moshe Inbar ◽

Shahar Lev-Ari ◽

...

Keyword(s):

Breast Cancer ◽

Peripheral Neuropathy ◽

Cancer Patients ◽

Medical Records ◽

Preventive Intervention ◽

Sensory Neuropathy ◽

Control Group ◽

Motor Neuropathy ◽

Breast Cancer Patients ◽

Treatment Results

Background: Treatment of chemotherapy-induced peripheral neuropathy (CIPN), which affects approximately 30% to 40% of patients treated with neuropathy-causing agents, is mainly symptomatic. Currently available interventions are of little benefit. Study Design: This study was conducted as a retrospective analysis of the efficacy of acupuncture and reflexology in alleviating CIPN in breast cancer patients. Methods: Medical records of 30 consecutive breast cancer patients who received both chemotherapy and treatment for CIPN according to our Acupuncture and Reflexology Treatment for Neuropathy (ART-N) protocol between 2011 and 2012 were reviewed. Symptom severity was rated at baseline, during, and after treatment. Results: The records of 30 breast cancer patients who had been concomitantly treated with chemotherapy and ART-N for CIPN were retrieved. Two records were incomplete, leaving a total of 28 patients who were enrolled into the study. Twenty patients (71%) had sensory neuropathy, 7 (25%) had motor neuropathy, and 1 (4%) had both sensory and motor neuropathy. Only 2 (10%) of the 20 patients with grades 1 to 2 neuropathy still reported symptoms at 12 months since starting the ART-N protocol. All 8 patients who presented with grades 3 to 4 neuropathy were symptom-free at the 12-month evaluation. Overall, 26 patients (93%) had complete resolution of CIPN symptoms. Conclusion: The results of this study demonstrated that a joint protocol of acupuncture and reflexology has a potential to improve symptoms of CIPN in breast cancer patients. The protocol should be validated on a larger cohort with a control group. It also warrants testing as a preventive intervention.

Download Full-text

A phase iia trial of acupuncture to reduce chemotherapy-induced peripheral neuropathy severity during neoadjuvant or adjuvant weekly paclitaxel chemotherapy in breast cancer patients.

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.e22201 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. e22201-e22201

Author(s):

Ting Bao ◽

Andrew David Seidman ◽

Lauren Piulson ◽

Xi Chen ◽

Andrew J. Vickers ◽

...

Keyword(s):

Breast Cancer ◽

Peripheral Neuropathy ◽

Cancer Patients ◽

Weekly Paclitaxel ◽

Breast Cancer Patients

Download Full-text

Demographic and clinicopathologic characteristics of breast cancer patients with history of oral alendronate use.

Journal of Clinical Oncology ◽

10.1200/jco.2012.30.15_suppl.e11093 ◽

2012 ◽

Vol 30 (15_suppl) ◽

pp. e11093-e11093

Author(s):

Sercan Aksoy ◽

Mehmet Ali Nahit Sendur ◽

Sebnem Yaman ◽

Zafer Arik ◽

Nuriye Ozdemir ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Survival Data ◽

Lower Incidence ◽

Disease Free Survival ◽

Control Group ◽

Breast Cancer Patients ◽

Free Survival ◽

One Year ◽

Disease Free

e11093 Background: Bisphosphonates therapy reduces the risk of skeletally related complications in patients with bone metastases due to malignancy and bisphosphonates are the most common used agents in the treatment of osteoporosis. However, the effect on clinical and pathological properties of breast cancer with using oral alendronate has not been reported. We investigate retrospectively the demographic and clinico-pathological characteristics of patients with oral alendronate users for longer than 1 year, compared to non-users. Methods: Patients with breast cancer diagnosed from 1998 to 2010 in our clinic were retrospectively analyzed. Patient’s demographics including survival data and tumor characteristics were obtained from medical charts. Breast cancer patients who were taking oral alendronate more than 12 months at the time of breast cancer diagnosis were enrolled as an alendronate users (n=44), where the patients matched with the same age who were not taking oral alendronate were included as a control group (n=444). Results: A total of 488 patients were included in this study. Forty-four patients received an oral alendronate treatment more than one year and 444 patients were considered as nonusers. Median age of both alendronate users and nonusers was 57 (33-89). Lower incidence histological grade III, T3-T4 tumor, and node positivity was seen in alendronate users but not statistically significant. A similar trend for lower incidence of triple negative and higher incidence ER (P=0.13), PR (P=0.12) and HER2 positivity (P=0.21) was also seen in alendronate users but not statistically significant. Disease free survival rate was 150±28 months in alendronate users where as 70±24 months in nonusers (P=0.015). Median overall survival rates could not be obtained but higher in alendronate users but not statistically significant (P=0.13). Conclusions: The use of oral alendronate for longer than one year before the diagnosis of breast cancer was associated with better clinico-pathological properties and significantly improved disease free survival in breast cancer patients.

Download Full-text

A phase IIA trial of acupuncture to reduce chemotherapy-induced peripheral neuropathy severity during neoadjuvant or adjuvant weekly paclitaxel chemotherapy in breast cancer patients

European Journal of Cancer ◽

10.1016/j.ejca.2018.06.008 ◽

2018 ◽

Vol 101 ◽

pp. 12-19 ◽

Cited By ~ 17

Author(s):

Ting Bao ◽

Andrew D. Seidman ◽

Lauren Piulson ◽

Emily Vertosick ◽

Xi Chen ◽

...

Keyword(s):

Breast Cancer ◽

Peripheral Neuropathy ◽

Cancer Patients ◽

Weekly Paclitaxel ◽

Breast Cancer Patients

Download Full-text

The effects of an individualized exercise intervention on body composition in breast cancer patients undergoing treatment

Sao Paulo Medical Journal ◽

10.1590/s1516-31802007000100005 ◽

2007 ◽

Vol 125 (1) ◽

pp. 22-28 ◽

Cited By ~ 54

Author(s):

Claudio Battaglini ◽

Martim Bottaro ◽

Carolyn Dennehy ◽

Logan Rae ◽

Edgar Shields ◽

...

Keyword(s):

Breast Cancer ◽

Body Composition ◽

Resistance Training ◽

Cancer Treatment ◽

Cancer Patients ◽

Exercise Intervention ◽

Exercise Group ◽

Moderate Intensity ◽

Control Group ◽

Breast Cancer Patients

CONTEXT AND OBJECTIVE: Changes in metabolism have been reported in the majority of patients undergoing cancer treatment, and these are usually characterized by progressive change in body composition. The effects of aerobic exercise programs to combat the cancer and cancer treatment-related side effects, which include the negative changes in body composition, have been extensively reported in the literature. However, few resistance exercise intervention studies have hypothesized that breast cancer patients might benefit from this type of exercise. The purpose of this study was to determine whether exercise protocols that emphasize resistance training would change body composition and strength in breast cancer patients undergoing treatment. DESIGN AND SETTING: Randomized controlled trial, at the Campus Recreation Center and Rocky Mountain Cancer Rehabilitation Institute of the University of Northern Colorado, and the North Colorado Medical Center. METHODS: Twenty inactive breast cancer patients were randomly assigned to a 21-week exercise group (n = 10) or a control group (n = 10). The exercise group trained at low to moderate intensity for 60 minutes on two days/week. The primary outcome measurements included body composition (skinfold method) and muscle strength (one repetition maximum). RESULTS: Significant differences in lean body mass, body fat and strength (p = 0.004, p = 0.004, p = 0.025, respectively) were observed between the groups at the end of the study. CONCLUSION: The results suggest that exercise emphasizing resistance training promotes positive changes in body composition and strength in breast cancer patients undergoing treatment.

Download Full-text

Interleukin-10 Levels are Associated with Doxorubicin-Related Cardiotoxicity in Breast Cancer Patients in a One-Year Follow-Up Study

Immunological Investigations ◽

10.1080/08820139.2021.1882486 ◽

2021 ◽

pp. 1-16

Author(s):

Michelle Teodoro Alves ◽

Ricardo Simões ◽

Rodrigo Mendonça Cardoso Pestana ◽

Angélica Navarro de Oliveira ◽

Heloísa Helena Marques Oliveira ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Interleukin 10 ◽

Breast Cancer Patients ◽

Follow Up Study ◽

One Year

Download Full-text

Exploring The Clinical Significance of Serum Angiopoietin-2 In Breast Cancer Patients

QJM ◽

10.1093/qjmed/hcab091.014 ◽

2021 ◽

Vol 114 (Supplement_1) ◽

Author(s):

Abeer I Abd Elmagid ◽

Hala Abdel Al ◽

Wessam El Sayed Saad ◽

Seham Kamal Mohamed

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Serum Levels ◽

Tnm Staging ◽

Control Group ◽

Healthy Controls ◽

Breast Cancer Patients ◽

Female Patients ◽

Significant Difference ◽

Angiopoietin 2

Abstract Background Breast cancer is the most common cancer among women and one of the most important causes of death among them.Angiogenesis is an important step for primary tumor growth, invasiveness, and metastases. Angiopoietins are well-recognized endothelial growth factors that are involved in angiogenesis associated with tumors. Aim To explore the diagnostic significance of serum angiopoietin-2 (Ang-2) in breast cancer and to evaluate its prognostic efficacy through studying the degree of its association with the TNM staging of the disease. Patients and Methods This study was conducted on (35) Egyptian female patients who were diagnosed as breast cancer according to histopathological examination of breast biopsy (Group 1, Breast Cancer Patients) and (25) female patients with benign breast diseases (Group II, Pathological Control Patients), in addition to (20) age - matched apparently healthy, free mammogram, females serving as healthy controls (Group III, Healthy Controls). For all participants, measurement of serum Ang-2 was done using enzyme linked immunosorbent assay (ELISA) technique. Results A highly significant increased levels of Ang-2 was observed in breast cancer patients when compared to healthy control group (Z = 4.95, p < 0.01). However, no significant difference was observed in Ang-2 levels between breast cancer patients group and pathological control group (Z = 3.37, p > 0.05). No significant difference was detected in Ang-2 levels in relation to TNM stage and histological grade. No significant correlation was found between Ang-2 levels and serum levels of CA15-3, hormone receptors, HER2/new receptor status (p > 0.05, respectively). Conclusion This study revealed that Ang-2 serum levels were significantly increased in patient with breast cancer compared with healthy controls, indicating that high Ang-2 level is a promising non invasive biomarker for breast cancer diagnosis. However, no significant difference of Ang-2 levels was detected in relation of breast TNM staging in the population studied.

Download Full-text